Elevance Beat Earnings by $1.24 - and Fell 9%. Here's Why.
🎙 Listen — Q&A podcast
Initiating coverage · Q2 CY2026 10-Q (filed July 15, 2026) on an FY2025 10-K base · Data verified against SEC filings via RoboSystems · Market data as of July 16, 2026
The Hook
On July 15, 2026, Elevance Health beat Wall Street's earnings estimate by $1.24 a share, raised its full-year guidance, and raised its cash flow outlook. The stock fell 8.7 percent - and dragged the entire managed-care sector down with it.
That reaction only makes sense when you see the five-year picture. Elevance grew total revenue from $138.6 billion in 2021 to $199.1 billion in 2025 - sixty billion dollars of new revenue, a 9.5 percent compound growth rate, the scale of a top-20 American company. Over those same five years, GAAP net income went down: $6.1 billion in 2021 to $5.7 billion in 2025. Every dollar of growth was eaten by medical costs. The market is no longer paying for Elevance's top line; it is pricing the question of whether the earnings engine underneath ever catches up.
Company Snapshot
Elevance Health - the former Anthem, renamed in 2022 - is one of the largest health insurers in the United States, serving 44.9 million medical members and touching roughly 104 million consumers overall. It operates the Blue Cross / Blue Shield franchise in 14 states, plus the Wellpoint brand, and runs two businesses: Health Benefits (the insurance engine - commercial, Individual ACA, Medicare, Medicaid, Federal Employee Program) and Carelon (the services engine - CarelonRx pharmacy services and Carelon Services health solutions). It reports on a calendar fiscal year.
This piece is built on the just-filed Q2 2026 10-Q (filed July 15, 2026) layered over the FY2025 10-K (filed February 6, 2026). Note the company's own terminology: what most insurers call the medical loss ratio, Elevance discloses as the "benefit expense ratio."
The Financial Story
The scissors: revenue up 44 percent, profit down 8 percent. The verified five-year revenue line reads $138.6B (2021), $156.6B (2022), $171.3B (2023), $177.0B (2024), $199.1B (2025). GAAP net income over the same years: $6.1B, $5.9B, $6.0B, $6.0B, $5.7B. Diluted GAAP EPS has been pinned near $25 for five straight years ($24.95 in 2021, $25.21 in 2025) - and even that flatness is flattering, because roughly $2.6 billion a year of buybacks shrank the share count while the profit dollars shrank too. The so-what: Elevance's growth has been in exactly the businesses - Medicaid and Medicare - where reimbursement rates have lagged how sick the members actually are.
Q2 2026 made the squeeze explicit. Operating revenue rose 0.8 percent to $49.8 billion, but the benefit expense ratio hit 89.7 percent, up 80 basis points year over year - meaning nearly 90 cents of every premium dollar went straight out the door as medical costs. Total operating gain fell 27 percent to $1.8 billion, and the Health Benefits segment's operating margin nearly halved, from 3.8 percent to 2.1 percent. GAAP shareholders' net income fell 16 percent to $1.46 billion ($6.71 diluted). The headline "beat" - adjusted EPS of $7.45 against a $6.21 consensus - was real but flattered by an approximately $0.80-per-share below-the-line benefit, mostly investment-income valuation adjustments, which management says it will plow back into one-time second-half investments rather than let flow to the bottom line. The market saw through the beat to the margin line, which is why the stock fell.
Medicaid is the epicenter - and management called the bottom. Elevance runs roughly $57 billion of annualized Medicaid revenue at a full-year operating margin it guides to approximately negative 1.75 percent. On the call, CEO Gail Boudreaux and CFO Mark Kaye repeatedly called 2026 the "trough year" for Medicaid margins: July rate updates came in at the upper end of mid-single digits (better than planned), acuity is no longer resetting the way it did post-redetermination, and cost pressure is concentrated in identifiable categories - behavioral health, specialty pharmacy, outpatient surgery, emergency department use. The company is also pruning: it agreed to exit the D.C. Medicaid market and expects to exit more states over the next 12 to 18 months where it sees no path to sustainable returns. Membership reflects the reset: total medical members fell 1.5 percent year over year to 44.9 million, with Medicare Advantage down 15.9 percent (a deliberate repositioning toward profitability - MA is now tracking to at least a 2 percent margin this year) and Medicaid down 4.3 percent on redeterminations.
Carelon is the offset. While the insurance engine compressed, the services engine grew: Carelon operating revenue rose 6 percent to $19.2 billion in the quarter - CarelonRx up 5.7 percent to $11.3 billion, Carelon Services up 7.2 percent to $8.0 billion - with $0.9 billion of operating gain. It is not yet big enough to carry the enterprise (Health Benefits still produced $896 million of quarterly operating gain even in a trough quarter), but it is the structural answer to the margin squeeze: revenue that does not carry an 89.7 percent benefit ratio.
Cash flow tells a harsher five-year story than earnings - with a 2026 inflection. Annual operating cash flow fell from $8.4 billion in 2022 to $4.3 billion in 2025, a 49 percent decline. That is what it looks like when claims grow faster than premiums for three years. The counterpoint: first-half 2026 operating cash flow doubled year over year to $6.2 billion (flattered by a state Medicaid pass-through payment received in June and remitted in July), and full-year guidance was raised to at least $6.0 billion. The balance sheet is stable - $126.4 billion of assets, $31.0 billion of total debt, $44.9 billion of shareholders' equity - and the company still returned capital in the quarter ($234 million of buybacks, $373 million of dividends, $5.3 billion of repurchase authorization remaining).
One real tail risk was removed this quarter. In February 2026, CMS notified Elevance of issues with historical Medicare Advantage risk-adjustment data (diagnosis codes for service dates 2015 through April 2023). Elevance accrued $935 million - $4.27 per share - as its best estimate of the exposure and remitted an initial $342 million in Q2. Per the 10-Q: on July 13, 2026, CMS confirmed in writing that all required steps were completed, sanctions will not be imposed, and the enforcement matter is closed. A regulatory overhang that could have threatened its Medicare franchise was resolved in five months for a known number.
Valuation - What It's Worth as a Normal Business
Where it trades. At roughly $379 (intraday July 16, 2026, down another 3 percent on top of the 8.7 percent earnings-day drop), Elevance carries a market cap near $82 billion. That is 16.9 times trailing GAAP earnings, 14.0 times the raised FY2026 adjusted-EPS guide of at least $27.00, and roughly 13.0 times the 2027 earnings management's framework implies (at least 12 percent growth off an at-least-$26 baseline, or about $29.10). It trades at 0.41 times FY2025 revenue, a free-cash-flow yield in the 6 to 7 percent range on normalized cash generation, and a 1.8 percent dividend yield. Analyst consensus sits near a Buy with an average target around $448. The peer board (forward P/E, July 16): UnitedHealth about 22 times, Centene about 19 times, Humana about 39 times (depressed earnings base), Cigna about 10 times. Elevance sits near the bottom of the group - priced closer to the pharmacy-benefit-manager comp than to its managed-care peers.
Scenario DCF. A ten-year free-cash-flow-to-equity model on 217.9 million diluted shares, using normalized FCF as the starting point:
| Scenario | Starting FCF | Growth (yrs 1-5, then 6-10) | Terminal growth | Discount rate | Implied equity value | Per share |
|---|---|---|---|---|---|---|
| Bear | $4.5B | 2%, then 1% | 1.5% | 9.5% | ~$57B | ~$265 |
| Base | $5.5B | 7%, then 4% | 2.5% | 9.0% | ~$110B | ~$505 |
| Bull | $5.8B | 8.5%, then 4.5% | 2.25% | 8.75% | ~$128B | ~$590 |
The bear case assumes Medicaid rates never catch up, margins stay near trough, and Carelon growth only offsets insurance erosion. The base case assumes the trough-year thesis holds: rates re-align through 2027-2028, MA margin repair continues, and Carelon compounds. The bull adds successful Medicaid market pruning and the 12-percent-plus EPS algorithm sustained past 2027.
Peer / historical re-rating. On the guided at-least-$27.00: 15 times earns $405, 17 times earns $459. On the 2027 framework EPS of about $29.10: 13 times is $379 - today's price - while 15 times is $437 and 17 times is $495.
What today's price implies. At $379, the market is paying 13 times next year's management-framework earnings - pricing in essentially zero multiple expansion and heavy discount on the "trough year" claim. Put differently: today's price is the bear-to-base midpoint. If 2026 really is the Medicaid bottom, the implied-value range under the stated assumptions sits meaningfully above the current quote; if rates lag acuity for another two years, the bear case says the stock is roughly fair. These are implied values under explicitly stated assumptions - not price targets, and not investment advice.
Risks
The risks are specific and mostly governmental. First, the core one: Medicaid rates are set by states on a lag, and if acuity or utilization (behavioral health, specialty pharmacy, ER, outpatient surgery) outruns the mid-single-digit rate updates, the "trough" slides to 2027 - management itself is not assuming second-half trend improvement. Second, the One Big Beautiful Bill Act brings Medicaid work requirements and eligibility verification that touch roughly 20 percent of Elevance's Medicaid book (expansion and waiver members); management calls it phased and manageable, but it is a live enrollment headwind into 2027. Third, CMS said in May 2025 it would substantially expand Risk Adjustment Data Validation audits of Medicare Advantage plans - the just-closed notice cost $935 million, and the audit regime that produced it is intensifying, per the company's own 10-Q risk framing. Fourth, Star Ratings: 2026 bonus-year ratings improved (59 percent of MA members in 4.0-plus-Star plans, up from about 40 percent), but Stars math swings hundreds of millions in bonus revenue. Finally, follow-on antitrust cases from opt-outs of the Blue Cross Blue Shield subscriber and provider settlements remain pending, and the adjusted operating expense ratio is running 100 basis points hot on investment spending that has to actually produce the promised 2027 leverage.
The Bottom Line
Elevance is a $200 billion-revenue institution trading at 14 times guided earnings because five years of growth produced zero profit growth - and the market wants proof, not guidance, that 2026 is the bottom. The proof points are checkable each quarter: Medicaid rate updates (July's came in at the upper end of mid-single digits), the benefit expense ratio against the 89.7 percent Q2 mark, Medicare Advantage holding its at-least-2-percent margin, Carelon compounding above enterprise growth, and whether the at-least-12-percent 2027 EPS algorithm survives contact with the fall rate cycle. The CMS enforcement matter is closed, the balance sheet is intact, and the stock is priced for the skeptical case. This is a framework for watching the trough-year claim resolve - not a recommendation.
Built with RoboSystems - structured SEC filing data for every public company, queryable at robosystems.ai. New customers get 50% off your first month with code ROBO50.